Clinical trial · no report yet · Phase 1/Phase 2
RADIAN
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- NCT05784012 ↗
- Active, not recruiting
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Dostarlimab; Niraparib; cisplatin plus radiotherapy; Niraparib
- Arms
- Cohort A · Experimental
- Cohort B · Experimental
- Enrollment
- 34
- Primary outcomes
- 1-year disease free survival
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello with GlaxoSmithKline, MFAR
- Start
- Nov 13, 2023
- Primary completion
- Mar 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05784012 · updated Jun 4, 2026